Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup trial (SW0G S9003).

Abstract:

:We report an update on a prospective observational trial for Waldenstrom's macroglobulinemia (WM) that called for re-registration to treatment with fludarabine (30 mg/m(2)) upon the development of symptomatic or progressive disease. Patients who did not require therapy for more than 1 year (n = 54) could be distinguished from the 118 untreated patients requiring immediate therapy on the basis of hemoglobin, serum beta(2)-microglobulin (beta2m), C-reactive protein (CRP), albumin, and IgM levels, and lower incidence of extramedullary infiltration. Overall response rate (>or= partial response [PR]) to fludarabine was 38%, with 2% complete remissions (CRs). Event-free and overall survivals were significantly longer in the presence of lower levels of serum beta2m in all cohorts. Using time-dependent covariates, neither the occurrence of response (>or= PR) nor the time to response was associated with superior overall or event-free survival. These data support serum beta2m as the dominant prognostic indicator in WM, and show that this factor alone can provide valuable disease risk assessment. Response to therapy using current criteria is not a reliable predictor for survival in this disease.

journal_name

Semin Oncol

journal_title

Seminars in oncology

authors

Dhodapkar MV,Jacobson JL,Gertz MA,Crowley JJ,Barlogie B

doi

10.1053/sonc.2003.50050

subject

Has Abstract

pub_date

2003-04-01 00:00:00

pages

220-5

issue

2

eissn

0093-7754

issn

1532-8708

pii

S0093775403000174

journal_volume

30

pub_type

临床试验,杂志文章
  • Prognostic factors in metastatic germ cell tumors.

    abstract::Metastatic germ cell cancer is a very heterogeneous group with respect to prognosis under cisplatinum-based chemotherapy. The main determinants of complete response and survival are not only the extension of the metastases but much more the biology of the underlying tumor which is represented by the location of the me...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Schmoll HJ,Beyer J

    更新日期:1998-04-01 00:00:00

  • The Wayne State University Waldenstrom's Macroglobulinemia preclinical model for Waldenstrom's macroglobulinemia.

    abstract::The Wayne State University Waldenstrom's Macroglobulinemia xenograft model in mice with severe combined immune deficiency (WSU-WM-SCID) is the only preclinical animal model available for this disease. It is based on a permanent, EBV- IgMlambda cell line (WSU-WM) established from a patient with a 10-year history of Wal...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/sonc.2003.50043

    authors: Al-Katib AM,Mensah-Osman E,Aboukameel A,Mohammad R

    更新日期:2003-04-01 00:00:00

  • Treatment of cancer-related hypercalcemia.

    abstract::Hypercalcemia, a complication that develops in 10% to 20% of patients with cancer, results from disruption of the normal physiologic mechanisms that closely regulate calcium homeostasis. Most patients with hypercalcemia are seriously dehydrated, and this volume depletion further compromises the kidney's ability to exc...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Ritch PS

    更新日期:1990-04-01 00:00:00

  • Pathological and molecular evaluation of pancreatic neoplasms.

    abstract::Pancreatic neoplasms are morphologically and genetically heterogeneous and include a wide variety of tumors ranging from benign to malignant with an extremely poor clinical outcome. Our understanding of these pancreatic neoplasms has improved significantly with recent advances in cancer sequencing. Awareness of molecu...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2014.12.004

    authors: Rishi A,Goggins M,Wood LD,Hruban RH

    更新日期:2015-02-01 00:00:00

  • Fatigue: definitions, mechanisms, and paradigms for study.

    abstract::Interferon-alpha (IFN-alpha) therapy is frequently associated with significant fatigue, which is often the dominant dose-limiting side effect. The fatigue associated with IFN-alpha therapy is usually dose related, worsens with continued therapy, and is associated with significant depression. Although the direct cause ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Dalakas MC,Mock V,Hawkins MJ

    更新日期:1998-02-01 00:00:00

  • The emerging role of pemetrexed (Alimta) and gemcitabine in non-small cell lung cancer.

    abstract::In recent years, several new cytotoxic agents have been investigated for the management of non-small cell lung cancer (NSCLC), including the antimetabolic gemcitabine (Gemzar; Eli Lilly and Company, Indianapolis, IN) and the new multitargeted antifolate pemetrexed (Alimta, Eli Lilly and Company), which are both among ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(03)00284-7

    authors: Le Chevalier T

    更新日期:2003-08-01 00:00:00

  • Adjuvant and neoadjuvant therapy for early stage non-small cell lung cancer.

    abstract::Lung cancer is the number one cause of cancer-related death in both men and women in the United States. Non-small cell lung cancer accounts for approximately 85% of these cases. Despite complete resection, long-term survival for patients with operable disease remains poor. Studies exploring postoperative chemotherapy ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(01)90056-9

    authors: Pisters KM

    更新日期:2001-08-01 00:00:00

  • Antifolates in clinical development.

    abstract::Many novel antifolate compounds with unique pharmacologic properties are currently in clinical development. These newer antifolates differ from methotrexate, the most widely used and studied drug in this class, in terms of their lipid solubility and cellular transport affinity, their level of polyglutamation, and thei...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Takimoto CH

    更新日期:1997-10-01 00:00:00

  • Mind the gap: An analysis of foregone health gains from unfunded cancer medicines in New Zealand.

    abstract::Publicly funded cancer medicines listed on the New Zealand Pharmaceutical Schedule were compared with those listed on the Australian Pharmaceutical Benefits Scheme. To quantify the health gains offered by the cancer medicines funded in Australia but not in New Zealand, clinical trial data reporting median progression-...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2016.10.004

    authors: Evans J,Laking G,Strother M,Wang T,Metcalfe S,Blick G,Pauls R,Crausaz S

    更新日期:2016-12-01 00:00:00

  • Response patterns of recurrent glioblastomas treated with tumor-treating fields.

    abstract::Glioblastoma multiforme (GBM) is the most common form of primary malignant brain cancer. Median overall survival (OS) for newly diagnosed patients is only about 12 to 18 months. GBM tumors invariably recur, and there is no widely recognized and effective standard treatment for recurrent GBM. NovoTTF Therapy is a novel...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2014.09.009

    authors: Vymazal J,Wong ET

    更新日期:2014-10-01 00:00:00

  • Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.

    abstract::We report an open, three-armed, multicenter study being carried out to assess the optimum treatment for acute and delayed emesis and nausea in patients undergoing highly emetogenic chemotherapy. Eighty-seven patients were randomized to receive tropisetron (Navoban; Sandoz Pharma Ltd, Basel, Switzerland), tropisetron p...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Bruntsch U,Drechsler S,Eggert J,Gosse H,Ukena D,Imhoff W,Faerber L

    更新日期:1994-10-01 00:00:00

  • High-dose ifosfamide in the treatment of advanced soft tissue sarcomas.

    abstract::Ifosfamide, an oxazaphosphorine analogue, is now commonly used in first-line anthracycline-containing regimens for advanced soft tissue sarcomas, based on its demonstrated single-agent activity in previously treated patients. At the Institut Gustave-Roussy, we performed a phase II study of high-dose ifosfamide without...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Tursz T

    更新日期:1996-06-01 00:00:00

  • In vitro data supporting interferon plus cytotoxic agent combinations.

    abstract::The human tumor cloning system is an in vitro assay that has been used to predict response of patients' tumors to conventional antineoplastic agents as well as to biologic agents. In addition, the assay has been used to screen for antitumor activity of newly discovered cytotoxics and biologics. The purpose of the pres...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Von Hoff DD

    更新日期:1991-10-01 00:00:00

  • Biochemical effects of Navelbine on tubulin and associated proteins.

    abstract::Navelbine (NVB) or 5' nor-anhydro-vinblastine was shown to present a broader antitumor activity and to induce fewer side effects than vinblastine (VBL) or vincristine (VCR). The possible mechanisms of these differences were analyzed with in vitro methods. At substoichiometric concentrations, the three drugs inhibit mi...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Fellous A,Ohayon R,Vacassin T,Binet S,Lataste H,Krikorian A,Couzinier JP,Meininger V

    更新日期:1989-04-01 00:00:00

  • Topotecan and the treatment of recurrent ovarian cancer: is there a role for granulocyte colony-stimulating factor?

    abstract::Topotecan (Hycamtin; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) a new chemotherapeutic agent for the treatment of patients with advanced carcinoma of the ovary after failure of initial or subsequent therapy, is a specific, potent inhibitor of the enzyme topoisomerase I. Myelosuppression is the dose-limiting...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Saltz L,Janik JE

    更新日期:1997-02-01 00:00:00

  • On the frontline of screening for breast cancer.

    abstract::The mainstay of screening for breast cancer is the mammogram. There are several randomized control trials that demonstrate a significant decrease in breast cancer mortality when compared to women without screening mammography included in their care. Digital mammography has improved detection in the dense breast. With ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2010.11.004

    authors: D'Orsi CJ,Newell MS

    更新日期:2011-02-01 00:00:00

  • In situ analysis of the action of Navelbine on various types of microtubules using immunofluorescence.

    abstract::Preliminary clinical studies demonstrated that 5' nor-anhydro-vinblastine, Navelbine (NVB) has a broader antitumor activity and fewer neurotoxic effects than vinblastine or vincristine. The tectal plate anlage of mouse embryos at the earliest stages of neuronal differentiation were used to analyze and compare the effe...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Binet S,Fellous A,Lataste H,Krikorian A,Couzinier JP,Meininger V

    更新日期:1989-04-01 00:00:00

  • Three cycles versus six cycles of adjuvant paclitaxel (Taxol)/carboplatin in early stage ovarian cancer.

    abstract::The optimal management of early stage ovarian cancer with poor prognostic features remains controversial. On the basis of results of studies in advanced ovarian cancer, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) in combination with a platinum agent has become part of adjuvant chemotherapy trials i...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Young RC

    更新日期:2000-06-01 00:00:00

  • The use of ondansetron in patients receiving multiple-day cisplatin regimens.

    abstract::The control of nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy has remained difficult, even with the use of combination antiemetic regimens containing metoclopramide. Although these patients receive a lower daily dose of cisplatin, the emetogenic potential remains high. In addition, many ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Hainsworth JD

    更新日期:1992-08-01 00:00:00

  • Intraperitoneal cisplatin chemotherapy in the management of ovarian carcinoma.

    abstract::Phase I trials of the intraperitoneal (IP) administration of cisplatin have demonstrated that the drug can be safely delivered by this route with a major increase in exposure (approximately tenfold to 15-fold) of the cavity to the cytotoxic agent compared with that of the systemic circulation. Phase I trials of IP cis...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Markman M

    更新日期:1989-08-01 00:00:00

  • Early-stage non-small cell lung cancer: surgery, stereotactic radiosurgery, and individualized adjuvant therapy.

    abstract::Despite cures in early stage (IA-IIB) non-small cell lung cancer (NSCLC), the 5-year survival rate is only 36%-73%. Surgical resection via lobectomy is the treatment of choice in early-stage NSCLC, with the goal being complete anatomic resection of the tumor and mediastinal lymph node evaluation. Newer technologies, i...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2013.12.011

    authors: Padda SK,Burt BM,Trakul N,Wakelee HA

    更新日期:2014-02-01 00:00:00

  • Adjuvant therapy for gastric cancer.

    abstract::The curative management of gastric adenocarcinoma depends on complete resection of the primary tumor. In patients with lymph node metastases in the resected specimen, the relapse and death rates from recurrent cancer are 70% to 80%. There is continued debate over whether more extensive lymph node dissection (D2) impro...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(03)00298-7

    authors: Macdonald JS

    更新日期:2003-08-01 00:00:00

  • Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy in stage II and III breast cancer patients: preliminary results of a phase II and pharmacogenomic study.

    abstract::The purpose of this study is to evaluate the efficacy and safety of a biweekly neoadjuvant docetaxel/gemcitabine regimen in patients with histologically confirmed stage II and III breast cancer. In addition, a cDNA microarray study attempted to correlate pretreatment gene-expression profile with clinical and pathologi...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:10.1053/j.seminoncol.2004.03.025

    authors: Estévez LG,Sánchez-Rovira P,Dómine M,León A,Calvo I,Jaén A,Casado V,Rubio G,Daz M,Miró C,Lobo F

    更新日期:2004-04-01 00:00:00

  • Approaches to managing carboplatin-induced thrombocytopenia: focus on the role of amifostine.

    abstract::Thrombocytopenia is a significant problem for patients receiving prolonged or aggressive chemotherapy for malignancy. For carboplatin, it is the predominant dose-limiting toxicity and it is cumulative in nature. A number of agents have been evaluated for efficacy in reducing the problem of thrombocytopenia. Some have ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Budd GT,Ganapathi R,Wood L,Snyder J,McLain D,Bukowski RM

    更新日期:1999-04-01 00:00:00

  • Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia.

    abstract::In April 1990, the Argentine Group for Treatment of Acute Leukemia began a multicenter trial for the treatment of previously untreated acute myeloblastic leukemia patients who were under 21 years of age. Initial treatment consisted of an 8-day induction phase with cytarabine together with idarubicin on days 3 to 5 and...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:

    authors: Sackmann-Muriel F,Fernández-Barbieri MA,Santarelli MT,Matus-Ridley M,Rosso A,Negri-Aranguren P,Cerutti I,Gomel M,Kvicala R

    更新日期:1993-12-01 00:00:00

  • The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel Project.

    abstract::The supplanting of radical mastectomy by simple mastectomy and then by lumpectomy plus radiation, the use of adjuvant therapy to alter the natural course of breast and colorectal cancer, the use of tamoxifen for the prevention of breast cancer, and the dramatic improvement in survival demonstrated with the use of the ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2008.07.005

    authors: Wickerham DL,O'Connell MJ,Costantino JP,Cronin WM,Paik S,Geyer CE Jr,Ganz PA,Petrelli N,Mamounas EP,Julian TB,Wolmark N

    更新日期:2008-10-01 00:00:00

  • Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia.

    abstract::Preclinical models in vitro and in vivo have shown that tumor hypoxia alters the malignant cell phenotype, selecting for p53 mutations, stimulating angiogenesis and metastasis, and markedly reducing the efficacy of both radiotherapy and chemotherapy. Similarly, clinical studies measuring pretreatment tumor oxygen stat...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2002.31531

    authors: Gandara DR,Lara PN Jr,Goldberg Z,Le QT,Mack PC,Lau DH,Gumerlock PH

    更新日期:2002-02-01 00:00:00

  • Recommendations of follow-up after treatment of germ cell tumors.

    abstract::Patients diagnosed with germ cell tumors (GCT) are relatively young, and most are rendered disease-free by primary treatment. Also, second-line therapies in nearly all instances are potentially curative. Therefore, the schedule and modalities of follow-up testing are important issues in detecting recurrence of GCT and...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(03)00098-8

    authors: Kondagunta GV,Sheinfeld J,Motzer RJ

    更新日期:2003-06-01 00:00:00

  • Comparative metabolism of tamoxifen and DNA adduct formation and in vitro studies on genotoxicity.

    abstract::Tamoxifen has been demonstrated to be hepatocarcinogenic in some but not all strains of the laboratory rat and is not a carcinogen in the mouse. To resolve the question of whether tamoxifen is genotoxic in humans, many laboratories have studied its interspecies metabolism and its propensity to form DNA adducts. This r...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Tannenbaum SR

    更新日期:1997-02-01 00:00:00

  • Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer.

    abstract::Most cellular proto-oncogenes encode proteins that participate in signaling pathways by which cells receive and execute instructions that lead to mitogenesis, differentiation, lineage determination, cell migration, extracellular matrix production, and apoptosis, among others. These proto-oncogene protein products incl...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2002.31524

    authors: Arteaga CL,Khuri F,Krystal G,Sebti S

    更新日期:2002-02-01 00:00:00